1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma
1974
Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance
Mason J, DeVita V, Canellos G. Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance. Blood 1974, 44: 483-487. PMID: 4528824, DOI: 10.1182/blood.v44.4.483.483.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaPlatelet countGranulocytic leukemiaClinical significanceOccurrence of thrombocytosisElevated platelet countThrombohemorrhagic complicationsUntreated patientsMedian durationShorter survivalBlastic crisisNormal countsPatientsSubsequent courseThrombocytosisLeukemiaCountEntire courseGroupCourseComplicationsClinicIncidenceDiagnosis
1973
MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION
Young R, Chabner B, Canellos G, Schein P, Devita V. MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION. The Lancet 1973, 301: 1339-1343. PMID: 4122739, DOI: 10.1016/s0140-6736(73)91672-3.Peer-Reviewed Original ResearchConceptsMaintenance therapyIntermittent therapyAdvanced HodgkinMaintenance chemotherapyAdditional therapyComplete remissionInitial remissionMedian durationFurther therapyHodgkin's diseasePatientsTherapyRemissionEntire groupDiseaseChemotherapySignificant differencesSurvivalGroupPrednisoneRegimensComplicationsMustineVincristineInfection
1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDoseAdvanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.
Bagley C, Devita V, Berard C, Canellos G. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Annals Of Internal Medicine 1972, 76: 227-34. PMID: 5066691, DOI: 10.7326/0003-4819-76-2-227.Peer-Reviewed Original Research